Dupixent Lawsuit in Iowa - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Iowa's population of 3.2 million supports an estimated 24,000 Dupixent patients, with prescribing concentrated in the Des Moines, Cedar Rapids, and Iowa City medical corridors. The University of Iowa Hospitals and Clinics — home to the Holden Comprehensive Cancer Center, an NCI-designated comprehensive cancer center — provides the state's most advanced dermatopathology and cutaneous lymphoma diagnostic capabilities. Iowa's 2-year product liability SOL is standard, and the state's discovery rule is well-established for latent injuries. Iowa's federal districts have moderate pharmaceutical litigation experience, and the state's Midwestern jury pools are generally considered balanced and methodical in evaluating complex evidence. Des Moines's growing population and economic base have expanded the state's legal community and plaintiff bar capacity for pharmaceutical cases.

Written By

People's Justice Legal Research Team

Statute of Limitations

Iowa: 2 years for product liability (Iowa Code § 614.1(2)). Discovery rule applies — the limitations period begins when the plaintiff knew or should have known of the injury and its cause.

2 years from discovery of injury

Filing Venue

Where to File in Iowa

Iowa has two federal judicial districts: the Northern District (Cedar Rapids/Sioux City) and Southern District (Des Moines/Davenport). The Southern District handles most pharmaceutical litigation. Iowa follows a modified comparative fault system (51 percent bar) and does not cap compensatory damages in product liability cases. Iowa has historically been a moderate litigation environment.

Iowa Data

Exposure in Iowa

Source: IQVIA prescription data estimates

Source: Holden Comprehensive Cancer Center / NCI

Source: University of Iowa Health Care

FAQ

Frequently Asked Questions

See details below.

Back to Dupixent Lawsuit Lawsuit Overview